#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4. Discussion
1-1	0-2	4.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=This study examined whether the combined administration of 6.0 g of glycine and 0.4 g of tryptophan suppressed the elevation in serum uric acid levels induced by purine ingestion and increased urinary uric acid excretion .
2-1	14-18	This	event[2]	new[2]	coref	8-1[47_2]
2-2	19-24	study	event[2]	new[2]	_	_
2-3	25-33	examined	_	_	_	_
2-4	34-41	whether	_	_	_	_
2-5	42-45	the	organization[3]	new[3]	_	_
2-6	46-54	combined	organization[3]	new[3]	_	_
2-7	55-69	administration	organization[3]	new[3]	_	_
2-8	70-72	of	organization[3]	new[3]	_	_
2-9	73-76	6.0	organization[3]|quantity[4]	new[3]|new[4]	_	_
2-10	77-78	g	organization[3]|quantity[4]	new[3]|new[4]	_	_
2-11	79-81	of	organization[3]|quantity[4]	new[3]|new[4]	_	_
2-12	82-89	glycine	organization[3]|quantity[4]|substance	new[3]|new[4]|new	coref	4-1[23_0]
2-13	90-93	and	_	_	_	_
2-14	94-97	0.4	quantity[6]	new[6]	_	_
2-15	98-99	g	quantity[6]	new[6]	_	_
2-16	100-102	of	quantity[6]	new[6]	_	_
2-17	103-113	tryptophan	quantity[6]|substance	new[6]|new	coref	4-4
2-18	114-124	suppressed	_	_	_	_
2-19	125-128	the	abstract[8]	new[8]	coref	9-15[57_8]
2-20	129-138	elevation	abstract[8]	new[8]	_	_
2-21	139-141	in	abstract[8]	new[8]	_	_
2-22	142-147	serum	abstract[8]|abstract|abstract[12]	new[8]|new|new[12]	coref|coref	9-19|9-18[61_12]
2-23	148-152	uric	abstract[8]|abstract|abstract[12]	new[8]|new|new[12]	coref	2-33
2-24	153-157	acid	abstract[8]|substance|abstract[12]	new[8]|new|new[12]	coref	2-34
2-25	158-164	levels	abstract[8]|abstract[12]	new[8]|new[12]	_	_
2-26	165-172	induced	_	_	_	_
2-27	173-175	by	_	_	_	_
2-28	176-182	purine	animal|event[14]	new|new[14]	coref|coref	3-7[21_14]|9-25
2-29	183-192	ingestion	event[14]	new[14]	_	_
2-30	193-196	and	_	_	_	_
2-31	197-206	increased	event	new	none|none	2-31[0_270]|11-8
2-32	207-214	urinary	person|abstract[18]	new|new[18]	coref|coref	11-9|11-9[89_18]
2-33	215-219	uric	abstract|abstract[18]	giv|new[18]	coref	9-20
2-34	220-224	acid	substance|abstract[18]	giv|new[18]	coref	3-3
2-35	225-234	excretion	abstract[18]	new[18]	_	_
2-36	235-236	.	_	_	_	_

#Text=The amino acid doses used for single ingestion were based on those used in continual supplementation .
3-1	237-240	The	quantity[20]	new[20]	coref	5-5[30_20]
3-2	241-246	amino	quantity[20]	new[20]	_	_
3-3	247-251	acid	substance|quantity[20]	giv|new[20]	coref	9-21
3-4	252-257	doses	quantity[20]	new[20]	_	_
3-5	258-262	used	_	_	_	_
3-6	263-266	for	_	_	_	_
3-7	267-273	single	event[21]	giv[21]	coref	9-25[63_21]
3-8	274-283	ingestion	event[21]	giv[21]	_	_
3-9	284-288	were	_	_	_	_
3-10	289-294	based	_	_	_	_
3-11	295-297	on	_	_	_	_
3-12	298-303	those	_	_	_	_
3-13	304-308	used	_	_	_	_
3-14	309-311	in	_	_	_	_
3-15	312-321	continual	abstract[22]	new[22]	coref	8-10[51_22]
3-16	322-337	supplementation	abstract[22]	new[22]	_	_
3-17	338-339	.	_	_	_	_

#Text=Both glycine and tryptophan are present in dietary proteins that are ingested in normal daily living .
4-1	340-344	Both	substance[23]|substance[24]	giv[23]|new[24]	coref|coref	5-3[29_23]|7-13[44_24]
4-2	345-352	glycine	substance[23]|substance[24]	giv[23]|new[24]	_	_
4-3	353-356	and	substance[24]	new[24]	_	_
4-4	357-367	tryptophan	substance[24]|substance	new[24]|giv	coref	7-15[45_0]
4-5	368-371	are	_	_	_	_
4-6	372-379	present	_	_	_	_
4-7	380-382	in	_	_	_	_
4-8	383-390	dietary	abstract|substance[27]	new|new[27]	coref	10-48
4-9	391-399	proteins	substance[27]	new[27]	_	_
4-10	400-404	that	_	_	_	_
4-11	405-408	are	_	_	_	_
4-12	409-417	ingested	_	_	_	_
4-13	418-420	in	_	_	_	_
4-14	421-427	normal	abstract[28]	new[28]	_	_
4-15	428-433	daily	abstract[28]	new[28]	_	_
4-16	434-440	living	abstract[28]	new[28]	_	_
4-17	441-442	.	_	_	_	_

#Text=However , glycine at doses of up to 90 g per day administered over several weeks were reported no serious adverse effects .
5-1	443-450	However	_	_	_	_
5-2	451-452	,	_	_	_	_
5-3	453-460	glycine	substance[29]	giv[29]	coref	7-13[0_29]
5-4	461-463	at	substance[29]	giv[29]	_	_
5-5	464-469	doses	substance[29]|quantity[30]	giv[29]|giv[30]	_	_
5-6	470-472	of	substance[29]|quantity[30]	giv[29]|giv[30]	_	_
5-7	473-475	up	substance[29]|quantity[30]	giv[29]|giv[30]	_	_
5-8	476-478	to	substance[29]|quantity[30]	giv[29]|giv[30]	_	_
5-9	479-481	90	substance[29]|quantity[30]|quantity[31]	giv[29]|giv[30]|new[31]	_	_
5-10	482-483	g	substance[29]|quantity[30]|quantity[31]	giv[29]|giv[30]|new[31]	_	_
5-11	484-487	per	substance[29]|quantity[30]|quantity[31]	giv[29]|giv[30]|new[31]	_	_
5-12	488-491	day	substance[29]|quantity[30]|quantity[31]|time	giv[29]|giv[30]|new[31]|new	coref	6-12
5-13	492-504	administered	_	_	_	_
5-14	505-509	over	_	_	_	_
5-15	510-517	several	time[33]	new[33]	_	_
5-16	518-523	weeks	time[33]	new[33]	_	_
5-17	524-528	were	_	_	_	_
5-18	529-537	reported	_	_	_	_
5-19	538-540	no	abstract[34]	new[34]	coref	6-17[39_34]
5-20	541-548	serious	abstract[34]	new[34]	_	_
5-21	549-556	adverse	abstract[34]	new[34]	_	_
5-22	557-564	effects	abstract[34]	new[34]	_	_
5-23	565-566	.	_	_	_	_

#Text=The oral administration of up to 5.0 g of l-tryptophan per day did not lead to any adverse effects in young adult females .
6-1	567-570	The	organization[35]	new[35]	_	_
6-2	571-575	oral	organization[35]	new[35]	_	_
6-3	576-590	administration	organization[35]	new[35]	_	_
6-4	591-593	of	organization[35]	new[35]	_	_
6-5	594-596	up	organization[35]	new[35]	_	_
6-6	597-599	to	organization[35]	new[35]	_	_
6-7	600-603	5.0	organization[35]|quantity[36]	new[35]|new[36]	_	_
6-8	604-605	g	organization[35]|quantity[36]	new[35]|new[36]	_	_
6-9	606-608	of	organization[35]|quantity[36]	new[35]|new[36]	_	_
6-10	609-621	l-tryptophan	organization[35]|quantity[36]|substance[37]	new[35]|new[36]|new[37]	_	_
6-11	622-625	per	organization[35]|quantity[36]|substance[37]	new[35]|new[36]|new[37]	_	_
6-12	626-629	day	organization[35]|quantity[36]|substance[37]|time	new[35]|new[36]|new[37]|giv	_	_
6-13	630-633	did	_	_	_	_
6-14	634-637	not	_	_	_	_
6-15	638-642	lead	_	_	_	_
6-16	643-645	to	_	_	_	_
6-17	646-649	any	abstract[39]	giv[39]	coref	7-3[41_39]
6-18	650-657	adverse	abstract[39]	giv[39]	_	_
6-19	658-665	effects	abstract[39]	giv[39]	_	_
6-20	666-668	in	abstract[39]	giv[39]	_	_
6-21	669-674	young	abstract[39]|person[40]	giv[39]|new[40]	_	_
6-22	675-680	adult	abstract[39]|person[40]	giv[39]|new[40]	_	_
6-23	681-688	females	abstract[39]|person[40]	giv[39]|new[40]	_	_
6-24	689-690	.	_	_	_	_

#Text=Therefore , no adverse effects were attributed to the combined administration of glycine and tryptophan in the current trial .
7-1	691-700	Therefore	_	_	_	_
7-2	701-702	,	_	_	_	_
7-3	703-705	no	abstract[41]	giv[41]	coref	19-21[170_41]
7-4	706-713	adverse	abstract[41]	giv[41]	_	_
7-5	714-721	effects	abstract[41]	giv[41]	_	_
7-6	722-726	were	_	_	_	_
7-7	727-737	attributed	_	_	_	_
7-8	738-740	to	_	_	_	_
7-9	741-744	the	organization[42]	new[42]	_	_
7-10	745-753	combined	organization[42]	new[42]	_	_
7-11	754-768	administration	organization[42]	new[42]	_	_
7-12	769-771	of	organization[42]	new[42]	_	_
7-13	772-779	glycine	organization[42]|substance|substance[44]	new[42]|giv|giv[44]	coref	9-10
7-14	780-783	and	organization[42]|substance[44]	new[42]|giv[44]	_	_
7-15	784-794	tryptophan	organization[42]|substance[44]|substance[45]	new[42]|giv[44]|giv[45]	coref	8-10[0_45]
7-16	795-797	in	organization[42]|substance[44]|substance[45]	new[42]|giv[44]|giv[45]	_	_
7-17	798-801	the	organization[42]|substance[44]|substance[45]|event[46]	new[42]|giv[44]|giv[45]|new[46]	_	_
7-18	802-809	current	organization[42]|substance[44]|substance[45]|event[46]	new[42]|giv[44]|giv[45]|new[46]	_	_
7-19	810-815	trial	organization[42]|substance[44]|substance[45]|event[46]	new[42]|giv[44]|giv[45]|new[46]	_	_
7-20	816-817	.	_	_	_	_

#Text=This study confirmed the safety of combined glycine and tryptophan supplementation .
8-1	818-822	This	event[47]	giv[47]	coref	9-1[52_47]
8-2	823-828	study	event[47]	giv[47]	_	_
8-3	829-838	confirmed	_	_	_	_
8-4	839-842	the	abstract[48]	new[48]	_	_
8-5	843-849	safety	abstract[48]	new[48]	_	_
8-6	850-852	of	abstract[48]	new[48]	_	_
8-7	853-861	combined	abstract[48]|substance[49]	new[48]|new[49]	_	_
8-8	862-869	glycine	abstract[48]|substance[49]	new[48]|new[49]	_	_
8-9	870-873	and	abstract[48]	new[48]	_	_
8-10	874-884	tryptophan	abstract[48]|substance|abstract[51]	new[48]|giv|giv[51]	coref|coref	9-12|12-6[95_51]
8-11	885-900	supplementation	abstract[48]|abstract[51]	new[48]|giv[51]	_	_
8-12	901-902	.	_	_	_	_

#Text=The current study demonstrated that the combined administration of glycine and tryptophan significantly suppressed the elevation in the serum uric acid levels caused by purine ingestion in healthy subjects .
9-1	903-906	The	event[52]	giv[52]	coref	11-18[93_52]
9-2	907-914	current	event[52]	giv[52]	_	_
9-3	915-920	study	event[52]	giv[52]	_	_
9-4	921-933	demonstrated	_	_	_	_
9-5	934-938	that	_	_	_	_
9-6	939-942	the	organization[53]	new[53]	coref	10-4[68_53]
9-7	943-951	combined	organization[53]	new[53]	_	_
9-8	952-966	administration	organization[53]	new[53]	_	_
9-9	967-969	of	organization[53]	new[53]	_	_
9-10	970-977	glycine	organization[53]|substance|substance[55]	new[53]|giv|new[55]	coref|coref	10-16|12-9[97_55]
9-11	978-981	and	organization[53]|substance[55]	new[53]|new[55]	_	_
9-12	982-992	tryptophan	organization[53]|substance[55]|substance	new[53]|new[55]|giv	coref	10-26
9-13	993-1006	significantly	_	_	_	_
9-14	1007-1017	suppressed	_	_	_	_
9-15	1018-1021	the	abstract[57]	giv[57]	coref	10-36[75_57]
9-16	1022-1031	elevation	abstract[57]	giv[57]	_	_
9-17	1032-1034	in	abstract[57]	giv[57]	_	_
9-18	1035-1038	the	abstract[57]|abstract[61]	giv[57]|giv[61]	coref	10-39[79_61]
9-19	1039-1044	serum	abstract[57]|abstract|abstract[61]	giv[57]|giv|giv[61]	coref	10-40
9-20	1045-1049	uric	abstract[57]|abstract|abstract[61]	giv[57]|giv|giv[61]	coref	10-41
9-21	1050-1054	acid	abstract[57]|substance|abstract[61]	giv[57]|giv|giv[61]	coref	10-7
9-22	1055-1061	levels	abstract[57]|abstract[61]	giv[57]|giv[61]	_	_
9-23	1062-1068	caused	_	_	_	_
9-24	1069-1071	by	_	_	_	_
9-25	1072-1078	purine	animal|event[63]	giv|giv[63]	coref	10-45[80_63]
9-26	1079-1088	ingestion	event[63]	giv[63]	_	_
9-27	1089-1091	in	_	_	_	_
9-28	1092-1099	healthy	person[64]	new[64]	_	_
9-29	1100-1108	subjects	person[64]	new[64]	_	_
9-30	1109-1110	.	_	_	_	_

#Text=The effect of the combined amino acid administration was stronger than that of the same glycine dose alone , indicating that a small amount of tryptophan provides an additional benefit to glycine alone in reducing the elevation in the serum uric acid levels after the ingestion of dietary purines .
10-1	1111-1114	The	abstract[65]	new[65]	_	_
10-2	1115-1121	effect	abstract[65]	new[65]	_	_
10-3	1122-1124	of	abstract[65]	new[65]	_	_
10-4	1125-1128	the	abstract[65]|organization[68]	new[65]|giv[68]	coref	19-26[173_68]
10-5	1129-1137	combined	abstract[65]|organization[68]	new[65]|giv[68]	_	_
10-6	1138-1143	amino	abstract[65]|object|organization[68]	new[65]|new|giv[68]	coref	27-25
10-7	1144-1148	acid	abstract[65]|substance|organization[68]	new[65]|giv|giv[68]	coref	10-42
10-8	1149-1163	administration	abstract[65]|organization[68]	new[65]|giv[68]	_	_
10-9	1164-1167	was	_	_	_	_
10-10	1168-1176	stronger	_	_	_	_
10-11	1177-1181	than	_	_	_	_
10-12	1182-1186	that	_	_	_	_
10-13	1187-1189	of	_	_	_	_
10-14	1190-1193	the	quantity[70]	new[70]	_	_
10-15	1194-1198	same	quantity[70]	new[70]	_	_
10-16	1199-1206	glycine	substance|quantity[70]	giv|new[70]	coref	10-32[74_0]
10-17	1207-1211	dose	quantity[70]	new[70]	_	_
10-18	1212-1217	alone	quantity[70]	new[70]	_	_
10-19	1218-1219	,	_	_	_	_
10-20	1220-1230	indicating	_	_	_	_
10-21	1231-1235	that	_	_	_	_
10-22	1236-1237	a	quantity[71]	new[71]	_	_
10-23	1238-1243	small	quantity[71]	new[71]	_	_
10-24	1244-1250	amount	quantity[71]	new[71]	_	_
10-25	1251-1253	of	quantity[71]	new[71]	_	_
10-26	1254-1264	tryptophan	quantity[71]|substance	new[71]|giv	coref	12-11
10-27	1265-1273	provides	_	_	_	_
10-28	1274-1276	an	abstract[73]	new[73]	_	_
10-29	1277-1287	additional	abstract[73]	new[73]	_	_
10-30	1288-1295	benefit	abstract[73]	new[73]	_	_
10-31	1296-1298	to	abstract[73]	new[73]	_	_
10-32	1299-1306	glycine	abstract[73]|substance[74]	new[73]|giv[74]	coref	11-7[0_74]
10-33	1307-1312	alone	abstract[73]|substance[74]	new[73]|giv[74]	_	_
10-34	1313-1315	in	_	_	_	_
10-35	1316-1324	reducing	_	_	_	_
10-36	1325-1328	the	abstract[75]	giv[75]	coref	15-7[118_75]
10-37	1329-1338	elevation	abstract[75]	giv[75]	_	_
10-38	1339-1341	in	abstract[75]	giv[75]	_	_
10-39	1342-1345	the	abstract[75]|abstract[79]	giv[75]|giv[79]	coref	14-10[111_79]
10-40	1346-1351	serum	abstract[75]|abstract|abstract[79]	giv[75]|giv|giv[79]	coref	27-3
10-41	1352-1356	uric	abstract[75]|abstract|abstract[79]	giv[75]|giv|giv[79]	coref	11-10
10-42	1357-1361	acid	abstract[75]|substance|abstract[79]	giv[75]|giv|giv[79]	coref	11-11
10-43	1362-1368	levels	abstract[75]|abstract[79]	giv[75]|giv[79]	_	_
10-44	1369-1374	after	abstract[75]|abstract[79]	giv[75]|giv[79]	_	_
10-45	1375-1378	the	abstract[75]|abstract[79]|event[80]	giv[75]|giv[79]|giv[80]	_	_
10-46	1379-1388	ingestion	abstract[75]|abstract[79]|event[80]	giv[75]|giv[79]|giv[80]	_	_
10-47	1389-1391	of	abstract[75]|abstract[79]|event[80]	giv[75]|giv[79]|giv[80]	_	_
10-48	1392-1399	dietary	abstract[75]|abstract[79]|event[80]|abstract|substance[82]	giv[75]|giv[79]|giv[80]|giv|new[82]	_	_
10-49	1400-1407	purines	abstract[75]|abstract[79]|event[80]|substance[82]	giv[75]|giv[79]|giv[80]|new[82]	_	_
10-50	1408-1409	.	_	_	_	_

#Text=In agreement with previous reports , glycine increased urinary uric acid excretion and enhanced urate clearance in the current study .
11-1	1410-1412	In	_	_	_	_
11-2	1413-1422	agreement	abstract[83]	new[83]	_	_
11-3	1423-1427	with	abstract[83]	new[83]	_	_
11-4	1428-1436	previous	abstract[83]|abstract[84]	new[83]|new[84]	_	_
11-5	1437-1444	reports	abstract[83]|abstract[84]	new[83]|new[84]	_	_
11-6	1445-1446	,	_	_	_	_
11-7	1447-1454	glycine	substance	giv	coref	12-9
11-8	1455-1464	increased	event	new	none	14-7
11-9	1465-1472	urinary	person|abstract[89]|abstract[90]	giv|giv[89]|new[90]	coref|coref|coref	12-17|14-13[114_89]|15-28[134_90]
11-10	1473-1477	uric	abstract|abstract[89]|abstract[90]	giv|giv[89]|new[90]	coref	14-5
11-11	1478-1482	acid	substance|abstract[89]|abstract[90]	giv|giv[89]|new[90]	coref	14-5[109_0]
11-12	1483-1492	excretion	abstract[89]|abstract[90]	giv[89]|new[90]	_	_
11-13	1493-1496	and	abstract[90]	new[90]	_	_
11-14	1497-1505	enhanced	abstract[90]|abstract[92]	new[90]|new[92]	coref	15-33[136_92]
11-15	1506-1511	urate	abstract[90]|abstract|abstract[92]	new[90]|new|new[92]	coref	15-33
11-16	1512-1521	clearance	abstract[90]|abstract[92]	new[90]|new[92]	_	_
11-17	1522-1524	in	_	_	_	_
11-18	1525-1528	the	event[93]	giv[93]	coref	24-2[203_93]
11-19	1529-1536	current	event[93]	giv[93]	_	_
11-20	1537-1542	study	event[93]	giv[93]	_	_
11-21	1543-1544	.	_	_	_	_

#Text=The authors previously reported that continual supplementation with glycine and tryptophan led to an increase in urinary pH .
12-1	1545-1548	The	person[94]	new[94]	_	_
12-2	1549-1556	authors	person[94]	new[94]	_	_
12-3	1557-1567	previously	_	_	_	_
12-4	1568-1576	reported	_	_	_	_
12-5	1577-1581	that	_	_	_	_
12-6	1582-1591	continual	abstract[95]	giv[95]	coref	15-16[124_95]
12-7	1592-1607	supplementation	abstract[95]	giv[95]	_	_
12-8	1608-1612	with	abstract[95]	giv[95]	_	_
12-9	1613-1620	glycine	abstract[95]|substance|substance[97]	giv[95]|giv|giv[97]	coref|coref	13-1|15-14[122_97]
12-10	1621-1624	and	abstract[95]|substance[97]	giv[95]|giv[97]	_	_
12-11	1625-1635	tryptophan	abstract[95]|substance[97]|substance	giv[95]|giv[97]|giv	coref	15-16
12-12	1636-1639	led	_	_	_	_
12-13	1640-1642	to	_	_	_	_
12-14	1643-1645	an	abstract[99]	new[99]	_	_
12-15	1646-1654	increase	abstract[99]	new[99]	_	_
12-16	1655-1657	in	abstract[99]	new[99]	_	_
12-17	1658-1665	urinary	abstract[99]|person|abstract[101]	new[99]|giv|new[101]	coref|coref	14-10[0_101]|15-10
12-18	1666-1668	pH	abstract[99]|abstract[101]	new[99]|new[101]	_	_
12-19	1669-1670	.	_	_	_	_

#Text=Glycine exhibits a buffering action and it is often used as an antacid .
13-1	1671-1678	Glycine	substance	giv	coref	15-14
13-2	1679-1687	exhibits	_	_	_	_
13-3	1688-1689	a	abstract[104]	new[104]	ana	13-7[0_104]
13-4	1690-1699	buffering	abstract|abstract[104]	new|new[104]	_	_
13-5	1700-1706	action	abstract[104]	new[104]	_	_
13-6	1707-1710	and	_	_	_	_
13-7	1711-1713	it	abstract	giv	coref	22-6[195_0]
13-8	1714-1716	is	_	_	_	_
13-9	1717-1722	often	_	_	_	_
13-10	1723-1727	used	_	_	_	_
13-11	1728-1730	as	_	_	_	_
13-12	1731-1733	an	_	_	_	_
13-13	1734-1741	antacid	_	_	_	_
13-14	1742-1743	.	_	_	_	_

#Text=The water solubility of uric acid increases with increasing pH levels and uric acid excretion is more favorable in alkaline urine than in acidic urine .
14-1	1744-1747	The	abstract[107]	new[107]	_	_
14-2	1748-1753	water	substance|abstract[107]	new|new[107]	_	_
14-3	1754-1764	solubility	abstract[107]	new[107]	_	_
14-4	1765-1767	of	abstract[107]	new[107]	_	_
14-5	1768-1772	uric	abstract[107]|abstract|substance[109]	new[107]|giv|giv[109]	coref|coref	14-13|14-14[0_109]
14-6	1773-1777	acid	abstract[107]|substance[109]	new[107]|giv[109]	_	_
14-7	1778-1787	increases	event	new	coref	29-1[247_0]
14-8	1788-1792	with	_	_	_	_
14-9	1793-1803	increasing	_	_	_	_
14-10	1804-1806	pH	abstract|abstract[111]	giv|giv[111]	coref|coref	15-10[120_0]|27-1[234_111]
14-11	1807-1813	levels	abstract[111]	giv[111]	_	_
14-12	1814-1817	and	abstract[111]	giv[111]	_	_
14-13	1818-1822	uric	abstract[111]|abstract|abstract[114]	giv[111]|giv|giv[114]	coref|coref	15-23|15-28[133_114]
14-14	1823-1827	acid	abstract[111]|substance|abstract[114]	giv[111]|giv|giv[114]	coref	15-22[129_0]
14-15	1828-1837	excretion	abstract[111]|abstract[114]	giv[111]|giv[114]	_	_
14-16	1838-1840	is	_	_	_	_
14-17	1841-1845	more	_	_	_	_
14-18	1846-1855	favorable	_	_	_	_
14-19	1856-1858	in	_	_	_	_
14-20	1859-1867	alkaline	substance[115]	new[115]	_	_
14-21	1868-1873	urine	substance[115]	new[115]	_	_
14-22	1874-1878	than	_	_	_	_
14-23	1879-1881	in	_	_	_	_
14-24	1882-1888	acidic	substance[116]	new[116]	_	_
14-25	1889-1894	urine	substance[116]	new[116]	_	_
14-26	1895-1896	.	_	_	_	_

#Text=Therefore , it is possible that the elevation in urinary pH caused by glycine and tryptophan supplementation enhanced the solubility of urinary uric acid , thereby elevating urinary uric acid excretion and urate clearance .
15-1	1897-1906	Therefore	_	_	_	_
15-2	1907-1908	,	_	_	_	_
15-3	1909-1911	it	abstract	new	cata	15-3[0_125]
15-4	1912-1914	is	_	_	_	_
15-5	1915-1923	possible	_	_	_	_
15-6	1924-1928	that	abstract[125]	new[125]	_	_
15-7	1929-1932	the	abstract[118]|abstract[125]	giv[118]|new[125]	coref	19-4[165_118]
15-8	1933-1942	elevation	abstract[118]|abstract[125]	giv[118]|new[125]	_	_
15-9	1943-1945	in	abstract[118]|abstract[125]	giv[118]|new[125]	_	_
15-10	1946-1953	urinary	abstract[118]|person|abstract[120]|abstract[125]	giv[118]|giv|giv[120]|new[125]	coref|coref	15-22|17-4[148_120]
15-11	1954-1956	pH	abstract[118]|abstract[120]|abstract[125]	giv[118]|giv[120]|new[125]	_	_
15-12	1957-1963	caused	abstract[125]	new[125]	_	_
15-13	1964-1966	by	abstract[125]	new[125]	_	_
15-14	1967-1974	glycine	substance|substance[122]|abstract[125]	giv|giv[122]|new[125]	coref	19-14
15-15	1975-1978	and	substance[122]|abstract[125]	giv[122]|new[125]	_	_
15-16	1979-1989	tryptophan	substance[122]|substance|abstract[124]|abstract[125]	giv[122]|giv|giv[124]|new[125]	coref|coref	24-6[204_124]|24-9
15-17	1990-2005	supplementation	substance[122]|abstract[124]|abstract[125]	giv[122]|giv[124]|new[125]	_	_
15-18	2006-2014	enhanced	abstract[125]	new[125]	_	_
15-19	2015-2018	the	abstract[125]|abstract[126]	new[125]|new[126]	_	_
15-20	2019-2029	solubility	abstract[125]|abstract[126]	new[125]|new[126]	_	_
15-21	2030-2032	of	abstract[125]|abstract[126]	new[125]|new[126]	_	_
15-22	2033-2040	urinary	abstract[125]|abstract[126]|person|substance[129]	new[125]|new[126]|giv|giv[129]	coref|coref	15-28|15-30[0_129]
15-23	2041-2045	uric	abstract[125]|abstract[126]|abstract|substance[129]	new[125]|new[126]|giv|giv[129]	coref	15-29
15-24	2046-2050	acid	abstract[125]|abstract[126]|substance[129]	new[125]|new[126]|giv[129]	_	_
15-25	2051-2052	,	_	_	_	_
15-26	2053-2060	thereby	_	_	_	_
15-27	2061-2070	elevating	_	_	_	_
15-28	2071-2078	urinary	person|abstract[133]|abstract[134]	giv|giv[133]|giv[134]	coref|coref|coref	17-6|19-29[176_133]|29-4[251_134]
15-29	2079-2083	uric	abstract|abstract[133]|abstract[134]	giv|giv[133]|giv[134]	coref	17-11
15-30	2084-2088	acid	substance|abstract[133]|abstract[134]	giv|giv[133]|giv[134]	coref	17-12
15-31	2089-2098	excretion	abstract[133]|abstract[134]	giv[133]|giv[134]	_	_
15-32	2099-2102	and	abstract[134]	giv[134]	_	_
15-33	2103-2108	urate	abstract[134]|abstract|abstract[136]	giv[134]|giv|giv[136]	coref|coref	19-33|19-33[178_136]
15-34	2109-2118	clearance	abstract[134]|abstract[136]	giv[134]|giv[136]	_	_
15-35	2119-2120	.	_	_	_	_

#Text=Previous studies provide physiological , physicochemical and clinical validation for the use of citrate salt in the treatment of some types of lithiasis .
16-1	2121-2129	Previous	abstract[137]	new[137]	coref	23-1[199_137]
16-2	2130-2137	studies	abstract[137]	new[137]	_	_
16-3	2138-2145	provide	_	_	_	_
16-4	2146-2159	physiological	abstract[138]	new[138]	_	_
16-5	2160-2161	,	abstract[138]	new[138]	_	_
16-6	2162-2177	physicochemical	abstract[138]	new[138]	_	_
16-7	2178-2181	and	abstract[138]	new[138]	_	_
16-8	2182-2190	clinical	abstract[138]	new[138]	_	_
16-9	2191-2201	validation	abstract[138]	new[138]	_	_
16-10	2202-2205	for	abstract[138]	new[138]	_	_
16-11	2206-2209	the	abstract[138]|abstract[139]	new[138]|new[139]	_	_
16-12	2210-2213	use	abstract[138]|abstract[139]	new[138]|new[139]	_	_
16-13	2214-2216	of	abstract[138]|abstract[139]	new[138]|new[139]	_	_
16-14	2217-2224	citrate	abstract[138]|abstract[139]|person|substance[141]	new[138]|new[139]|new|new[141]	coref	17-1
16-15	2225-2229	salt	abstract[138]|abstract[139]|substance[141]	new[138]|new[139]|new[141]	_	_
16-16	2230-2232	in	abstract[138]|abstract[139]|substance[141]	new[138]|new[139]|new[141]	_	_
16-17	2233-2236	the	abstract[138]|abstract[139]|substance[141]|abstract[142]	new[138]|new[139]|new[141]|new[142]	_	_
16-18	2237-2246	treatment	abstract[138]|abstract[139]|substance[141]|abstract[142]	new[138]|new[139]|new[141]|new[142]	_	_
16-19	2247-2249	of	abstract[138]|abstract[139]|substance[141]|abstract[142]	new[138]|new[139]|new[141]|new[142]	_	_
16-20	2250-2254	some	abstract[138]|abstract[139]|substance[141]|abstract[142]|abstract[143]	new[138]|new[139]|new[141]|new[142]|new[143]	_	_
16-21	2255-2260	types	abstract[138]|abstract[139]|substance[141]|abstract[142]|abstract[143]	new[138]|new[139]|new[141]|new[142]|new[143]	_	_
16-22	2261-2263	of	abstract[138]|abstract[139]|substance[141]|abstract[142]|abstract[143]	new[138]|new[139]|new[141]|new[142]|new[143]	_	_
16-23	2264-2273	lithiasis	abstract[138]|abstract[139]|substance[141]|abstract[142]|abstract[143]|abstract	new[138]|new[139]|new[141]|new[142]|new[143]|new	coref	17-11[152_0]
16-24	2274-2275	.	_	_	_	_

#Text=Citrate salts treatment substantially increased urinary pH in patients with uric acid lithiasis , however , there was no significant change in the amount of urinary uric acid .
17-1	2276-2283	Citrate	substance|substance[146]	giv|new[146]	coref|coref	18-10|18-10[161_146]
17-2	2284-2289	salts	substance[146]	new[146]	_	_
17-3	2290-2299	treatment	_	_	_	_
17-4	2300-2313	substantially	abstract[148]	giv[148]	coref	19-7[167_148]
17-5	2314-2323	increased	abstract[148]	giv[148]	_	_
17-6	2324-2331	urinary	person|abstract[148]	giv|giv[148]	coref	17-26
17-7	2332-2334	pH	abstract[148]	giv[148]	_	_
17-8	2335-2337	in	abstract[148]	giv[148]	_	_
17-9	2338-2346	patients	abstract[148]|person[149]	giv[148]|new[149]	_	_
17-10	2347-2351	with	abstract[148]|person[149]	giv[148]|new[149]	_	_
17-11	2352-2356	uric	abstract[148]|person[149]|abstract|abstract[152]	giv[148]|new[149]|giv|giv[152]	coref	17-27
17-12	2357-2361	acid	abstract[148]|person[149]|substance|abstract[152]	giv[148]|new[149]|giv|giv[152]	coref	17-26[157_0]
17-13	2362-2371	lithiasis	abstract[148]|person[149]|abstract[152]	giv[148]|new[149]|giv[152]	_	_
17-14	2372-2373	,	_	_	_	_
17-15	2374-2381	however	_	_	_	_
17-16	2382-2383	,	_	_	_	_
17-17	2384-2389	there	_	_	_	_
17-18	2390-2393	was	_	_	_	_
17-19	2394-2396	no	abstract[153]	new[153]	_	_
17-20	2397-2408	significant	abstract[153]	new[153]	_	_
17-21	2409-2415	change	abstract[153]	new[153]	_	_
17-22	2416-2418	in	abstract[153]	new[153]	_	_
17-23	2419-2422	the	abstract[153]|quantity[154]	new[153]|new[154]	_	_
17-24	2423-2429	amount	abstract[153]|quantity[154]	new[153]|new[154]	_	_
17-25	2430-2432	of	abstract[153]|quantity[154]	new[153]|new[154]	_	_
17-26	2433-2440	urinary	abstract[153]|quantity[154]|person|substance[157]	new[153]|new[154]|giv|giv[157]	coref|coref	19-7|19-30[0_157]
17-27	2441-2445	uric	abstract[153]|quantity[154]|abstract|substance[157]	new[153]|new[154]|giv|giv[157]	coref	19-29
17-28	2446-2450	acid	abstract[153]|quantity[154]|substance[157]	new[153]|new[154]|giv[157]	_	_
17-29	2451-2452	.	_	_	_	_

#Text=The mixture of amino acids might be superior to citrate salts in the prevention or treatment of hyperuricemia .
18-1	2453-2456	The	substance[158]	new[158]	_	_
18-2	2457-2464	mixture	substance[158]	new[158]	_	_
18-3	2465-2467	of	substance[158]	new[158]	_	_
18-4	2468-2473	amino	substance[158]|substance[159]	new[158]|new[159]	coref	27-24[242_159]
18-5	2474-2479	acids	substance[158]|substance[159]	new[158]|new[159]	_	_
18-6	2480-2485	might	_	_	_	_
18-7	2486-2488	be	_	_	_	_
18-8	2489-2497	superior	_	_	_	_
18-9	2498-2500	to	_	_	_	_
18-10	2501-2508	citrate	person|substance[161]	giv|giv[161]	_	_
18-11	2509-2514	salts	substance[161]	giv[161]	_	_
18-12	2515-2517	in	substance[161]	giv[161]	_	_
18-13	2518-2521	the	substance[161]|abstract[162]	giv[161]|new[162]	_	_
18-14	2522-2532	prevention	substance[161]|abstract[162]	giv[161]|new[162]	_	_
18-15	2533-2535	or	substance[161]	giv[161]	_	_
18-16	2536-2545	treatment	substance[161]|abstract[163]	giv[161]|new[163]	_	_
18-17	2546-2548	of	substance[161]|abstract[163]	giv[161]|new[163]	_	_
18-18	2549-2562	hyperuricemia	substance[161]|abstract[163]|abstract	giv[161]|new[163]|new	_	_
18-19	2563-2564	.	_	_	_	_

#Text=Herein , although the elevation of urinary pH induced by the ingestion of glycine alone was not significant compared with the effects of placebo , glycine administration enhanced uric acid excretion and urate clearance , raising the possibility of other mechanisms .
19-1	2565-2571	Herein	_	_	_	_
19-2	2572-2573	,	_	_	_	_
19-3	2574-2582	although	_	_	_	_
19-4	2583-2586	the	abstract[165]	giv[165]	coref	25-21[222_165]
19-5	2587-2596	elevation	abstract[165]	giv[165]	_	_
19-6	2597-2599	of	abstract[165]	giv[165]	_	_
19-7	2600-2607	urinary	abstract[165]|person|abstract[167]	giv[165]|giv|giv[167]	coref|coref	24-15|24-15[208_167]
19-8	2608-2610	pH	abstract[165]|abstract[167]	giv[165]|giv[167]	_	_
19-9	2611-2618	induced	_	_	_	_
19-10	2619-2621	by	_	_	_	_
19-11	2622-2625	the	substance[168]	new[168]	coref	27-15[0_168]
19-12	2626-2635	ingestion	substance[168]	new[168]	_	_
19-13	2636-2638	of	substance[168]	new[168]	_	_
19-14	2639-2646	glycine	substance[168]|substance	new[168]|giv	coref	19-26
19-15	2647-2652	alone	_	_	_	_
19-16	2653-2656	was	_	_	_	_
19-17	2657-2660	not	_	_	_	_
19-18	2661-2672	significant	_	_	_	_
19-19	2673-2681	compared	_	_	_	_
19-20	2682-2686	with	_	_	_	_
19-21	2687-2690	the	abstract[170]	giv[170]	_	_
19-22	2691-2698	effects	abstract[170]	giv[170]	_	_
19-23	2699-2701	of	abstract[170]	giv[170]	_	_
19-24	2702-2709	placebo	abstract[170]|abstract	giv[170]|new	_	_
19-25	2710-2711	,	abstract[170]	giv[170]	_	_
19-26	2712-2719	glycine	abstract[170]|substance|organization[173]	giv[170]|giv|giv[173]	coref	22-3
19-27	2720-2734	administration	abstract[170]|organization[173]	giv[170]|giv[173]	_	_
19-28	2735-2743	enhanced	abstract[170]	giv[170]	_	_
19-29	2744-2748	uric	abstract[170]|abstract|abstract[176]	giv[170]|giv|giv[176]	coref|coref	22-10|24-20[212_176]
19-30	2749-2753	acid	abstract[170]|substance|abstract[176]	giv[170]|giv|giv[176]	coref	22-10[197_0]
19-31	2754-2763	excretion	abstract[170]|abstract[176]	giv[170]|giv[176]	_	_
19-32	2764-2767	and	abstract[170]	giv[170]	_	_
19-33	2768-2773	urate	abstract[170]|abstract|abstract[178]	giv[170]|giv|giv[178]	coref|coref	20-1|24-23[214_178]
19-34	2774-2783	clearance	abstract[170]|abstract[178]	giv[170]|giv[178]	_	_
19-35	2784-2785	,	_	_	_	_
19-36	2786-2793	raising	_	_	_	_
19-37	2794-2797	the	abstract[179]	new[179]	_	_
19-38	2798-2809	possibility	abstract[179]	new[179]	_	_
19-39	2810-2812	of	abstract[179]	new[179]	_	_
19-40	2813-2818	other	abstract[179]|abstract[180]	new[179]|new[180]	_	_
19-41	2819-2829	mechanisms	abstract[179]|abstract[180]	new[179]|new[180]	_	_
19-42	2830-2831	.	_	_	_	_

#Text=Urate transporter 1 ( URAT1 ) , a primary reabsorptive urate transporter that is targeted by pyrazinamide , reportedly disables glycine-induced uricosuria .
20-1	2832-2837	Urate	animal|abstract[182]	giv|new[182]	appos|coref	20-5[0_182]|20-11
20-2	2838-2849	transporter	abstract[182]	new[182]	_	_
20-3	2850-2851	1	abstract[182]	new[182]	_	_
20-4	2852-2853	(	_	_	_	_
20-5	2854-2859	URAT1	abstract	giv	coref	20-8[185_0]
20-6	2860-2861	)	_	_	_	_
20-7	2862-2863	,	_	_	_	_
20-8	2864-2865	a	abstract[185]	giv[185]	coref	22-17[0_185]
20-9	2866-2873	primary	abstract[185]	giv[185]	_	_
20-10	2874-2886	reabsorptive	abstract[185]	giv[185]	_	_
20-11	2887-2892	urate	animal|abstract[185]	giv|giv[185]	coref	21-6
20-12	2893-2904	transporter	abstract[185]	giv[185]	_	_
20-13	2905-2909	that	_	_	_	_
20-14	2910-2912	is	_	_	_	_
20-15	2913-2921	targeted	_	_	_	_
20-16	2922-2924	by	_	_	_	_
20-17	2925-2937	pyrazinamide	object	new	coref	21-1
20-18	2938-2939	,	_	_	_	_
20-19	2940-2950	reportedly	_	_	_	_
20-20	2951-2959	disables	_	_	_	_
20-21	2960-2975	glycine-induced	substance[187]	new[187]	_	_
20-22	2976-2986	uricosuria	substance[187]	new[187]	_	_
20-23	2987-2988	.	_	_	_	_

#Text=Pyrazinamide may reflect the enhanced urate reabsorption following the exchange of its active metabolite .
21-1	2989-3001	Pyrazinamide	substance	giv	ana	21-12
21-2	3002-3005	may	_	_	_	_
21-3	3006-3013	reflect	_	_	_	_
21-4	3014-3017	the	abstract[190]	new[190]	_	_
21-5	3018-3026	enhanced	abstract[190]	new[190]	_	_
21-6	3027-3032	urate	substance|abstract[190]	giv|new[190]	coref	24-23
21-7	3033-3045	reabsorption	abstract[190]	new[190]	_	_
21-8	3046-3055	following	_	_	_	_
21-9	3056-3059	the	event[191]	new[191]	_	_
21-10	3060-3068	exchange	event[191]	new[191]	_	_
21-11	3069-3071	of	event[191]	new[191]	_	_
21-12	3072-3075	its	event[191]|substance|substance[193]	new[191]|giv|new[193]	_	_
21-13	3076-3082	active	event[191]|substance[193]	new[191]|new[193]	_	_
21-14	3083-3093	metabolite	event[191]|substance[193]	new[191]|new[193]	_	_
21-15	3094-3095	.	_	_	_	_

#Text=Thus , glycine may inhibit the reabsorptive action of uric acid , which is induced by URAT1 .
22-1	3096-3100	Thus	_	_	_	_
22-2	3101-3102	,	_	_	_	_
22-3	3103-3110	glycine	substance	giv	coref	23-10[201_0]
22-4	3111-3114	may	_	_	_	_
22-5	3115-3122	inhibit	_	_	_	_
22-6	3123-3126	the	abstract[195]	giv[195]	_	_
22-7	3127-3139	reabsorptive	abstract[195]	giv[195]	_	_
22-8	3140-3146	action	abstract[195]	giv[195]	_	_
22-9	3147-3149	of	abstract[195]	giv[195]	_	_
22-10	3150-3154	uric	abstract[195]|abstract|substance[197]	giv[195]|giv|giv[197]	coref|coref	24-18[210_0]|24-20[0_197]
22-11	3155-3159	acid	abstract[195]|substance[197]	giv[195]|giv[197]	_	_
22-12	3160-3161	,	_	_	_	_
22-13	3162-3167	which	_	_	_	_
22-14	3168-3170	is	_	_	_	_
22-15	3171-3178	induced	_	_	_	_
22-16	3179-3181	by	_	_	_	_
22-17	3182-3187	URAT1	abstract	giv	coref	23-12
22-18	3188-3189	.	_	_	_	_

#Text=Further studies are needed to elucidate the action of glycine on URAT1 .
23-1	3190-3197	Further	abstract[199]	giv[199]	coref	32-1[283_199]
23-2	3198-3205	studies	abstract[199]	giv[199]	_	_
23-3	3206-3209	are	_	_	_	_
23-4	3210-3216	needed	_	_	_	_
23-5	3217-3219	to	_	_	_	_
23-6	3220-3229	elucidate	_	_	_	_
23-7	3230-3233	the	abstract[200]	new[200]	coref	25-17[219_200]
23-8	3234-3240	action	abstract[200]	new[200]	_	_
23-9	3241-3243	of	abstract[200]	new[200]	_	_
23-10	3244-3251	glycine	abstract[200]|substance[201]	new[200]|giv[201]	coref	25-31[0_201]
23-11	3252-3254	on	abstract[200]|substance[201]	new[200]|giv[201]	_	_
23-12	3255-3260	URAT1	abstract[200]|substance[201]|substance	new[200]|giv[201]|giv	coref	25-7
23-13	3261-3262	.	_	_	_	_

#Text=In the current study , the supplementation with tryptophan alone had no influence on urinary pH , urinary uric acid excretion or urate clearance .
24-1	3263-3265	In	_	_	_	_
24-2	3266-3269	the	event[203]	giv[203]	coref	33-5[293_203]
24-3	3270-3277	current	event[203]	giv[203]	_	_
24-4	3278-3283	study	event[203]	giv[203]	_	_
24-5	3284-3285	,	_	_	_	_
24-6	3286-3289	the	abstract[204]	giv[204]	ana	25-25[0_204]
24-7	3290-3305	supplementation	abstract[204]	giv[204]	_	_
24-8	3306-3310	with	abstract[204]	giv[204]	_	_
24-9	3311-3321	tryptophan	abstract[204]|substance	giv[204]|giv	coref	25-5[216_0]
24-10	3322-3327	alone	_	_	_	_
24-11	3328-3331	had	_	_	_	_
24-12	3332-3334	no	abstract[206]	new[206]	coref	25-25[224_206]
24-13	3335-3344	influence	abstract[206]	new[206]	_	_
24-14	3345-3347	on	abstract[206]	new[206]	_	_
24-15	3348-3355	urinary	abstract[206]|person|abstract[208]	new[206]|giv|giv[208]	coref	24-18
24-16	3356-3358	pH	abstract[206]|abstract[208]	new[206]|giv[208]	_	_
24-17	3359-3360	,	abstract[206]	new[206]	_	_
24-18	3361-3368	urinary	abstract[206]|person|abstract[210]	new[206]|giv|giv[210]	coref|coref	25-21[0_210]|29-4
24-19	3369-3373	uric	abstract[206]|abstract[210]	new[206]|giv[210]	_	_
24-20	3374-3378	acid	abstract[206]|substance|abstract[212]	new[206]|giv|giv[212]	coref|coref	25-22|29-4[250_212]
24-21	3379-3388	excretion	abstract[206]|abstract[212]	new[206]|giv[212]	_	_
24-22	3389-3391	or	abstract[206]	new[206]	_	_
24-23	3392-3397	urate	abstract[206]|abstract|abstract[214]	new[206]|giv|giv[214]	coref	29-8[253_214]
24-24	3398-3407	clearance	abstract[206]|abstract[214]	new[206]|giv[214]	_	_
24-25	3408-3409	.	_	_	_	_

#Text=As the effect of tryptophan on URAT1 might be structurally difficult , tryptophan might have exerted an indirect action against uric acid elevation via its influence on the action of glycine .
25-1	3410-3412	As	_	_	_	_
25-2	3413-3416	the	abstract[215]	new[215]	_	_
25-3	3417-3423	effect	abstract[215]	new[215]	_	_
25-4	3424-3426	of	abstract[215]	new[215]	_	_
25-5	3427-3437	tryptophan	abstract[215]|substance[216]	new[215]|giv[216]	coref	25-13[0_216]
25-6	3438-3440	on	abstract[215]|substance[216]	new[215]|giv[216]	_	_
25-7	3441-3446	URAT1	abstract[215]|substance[216]|abstract	new[215]|giv[216]|giv	_	_
25-8	3447-3452	might	_	_	_	_
25-9	3453-3455	be	_	_	_	_
25-10	3456-3468	structurally	_	_	_	_
25-11	3469-3478	difficult	_	_	_	_
25-12	3479-3480	,	_	_	_	_
25-13	3481-3491	tryptophan	substance	giv	coref	26-3
25-14	3492-3497	might	_	_	_	_
25-15	3498-3502	have	_	_	_	_
25-16	3503-3510	exerted	_	_	_	_
25-17	3511-3513	an	abstract[219]	giv[219]	_	_
25-18	3514-3522	indirect	abstract[219]	giv[219]	_	_
25-19	3523-3529	action	abstract[219]	giv[219]	_	_
25-20	3530-3537	against	abstract[219]	giv[219]	_	_
25-21	3538-3542	uric	abstract[219]|abstract|abstract[222]	giv[219]|giv|giv[222]	coref|coref	26-12|11-8[0_222]
25-22	3543-3547	acid	abstract[219]|substance|abstract[222]	giv[219]|giv|giv[222]	coref	26-13
25-23	3548-3557	elevation	abstract[219]|abstract[222]	giv[219]|giv[222]	_	_
25-24	3558-3561	via	abstract[219]|abstract[222]	giv[219]|giv[222]	_	_
25-25	3562-3565	its	abstract[219]|abstract[222]|abstract|abstract[224]	giv[219]|giv[222]|giv|giv[224]	coref	30-12[261_0]
25-26	3566-3575	influence	abstract[219]|abstract[222]|abstract[224]	giv[219]|giv[222]|giv[224]	_	_
25-27	3576-3578	on	abstract[219]|abstract[222]|abstract[224]	giv[219]|giv[222]|giv[224]	_	_
25-28	3579-3582	the	abstract[219]|abstract[222]|abstract[224]|abstract[225]	giv[219]|giv[222]|giv[224]|new[225]	_	_
25-29	3583-3589	action	abstract[219]|abstract[222]|abstract[224]|abstract[225]	giv[219]|giv[222]|giv[224]|new[225]	_	_
25-30	3590-3592	of	abstract[219]|abstract[222]|abstract[224]|abstract[225]	giv[219]|giv[222]|giv[224]|new[225]	_	_
25-31	3593-3600	glycine	abstract[219]|abstract[222]|abstract[224]|abstract[225]|substance	giv[219]|giv[222]|giv[224]|new[225]|giv	coref	26-10[229_0]
25-32	3601-3602	.	_	_	_	_

#Text=Specifically , tryptophan might promote the direct action of glycine against uric acid elevation .
26-1	3603-3615	Specifically	_	_	_	_
26-2	3616-3617	,	_	_	_	_
26-3	3618-3628	tryptophan	substance	giv	coref	27-8
26-4	3629-3634	might	_	_	_	_
26-5	3635-3642	promote	_	_	_	_
26-6	3643-3646	the	event[228]	new[228]	_	_
26-7	3647-3653	direct	event[228]	new[228]	_	_
26-8	3654-3660	action	event[228]	new[228]	_	_
26-9	3661-3663	of	event[228]	new[228]	_	_
26-10	3664-3671	glycine	event[228]|substance[229]	new[228]|giv[229]	coref	28-1[0_229]
26-11	3672-3679	against	event[228]|substance[229]	new[228]|giv[229]	_	_
26-12	3680-3684	uric	event[228]|substance[229]|abstract|abstract[232]	new[228]|giv[229]|giv|giv[232]	coref	32-20
26-13	3685-3689	acid	event[228]|substance[229]|substance|abstract[232]	new[228]|giv[229]|giv|giv[232]	coref	32-21
26-14	3690-3699	elevation	event[228]|substance[229]|abstract[232]	new[228]|giv[229]|giv[232]	_	_
26-15	3700-3701	.	_	_	_	_

#Text=The maximum serum levels of glycine and tryptophan are achieved within an hour of ingestion , which is followed by rapid decreases as the amino acids are metabolized .
27-1	3702-3705	The	abstract[234]	giv[234]	coref	34-19[316_234]
27-2	3706-3713	maximum	abstract[234]	giv[234]	_	_
27-3	3714-3719	serum	substance|abstract[234]	giv|giv[234]	coref	31-8
27-4	3720-3726	levels	abstract[234]	giv[234]	_	_
27-5	3727-3729	of	abstract[234]	giv[234]	_	_
27-6	3730-3737	glycine	abstract[234]|substance|substance[236]	giv[234]|new|new[236]	coref	30-16[263_236]
27-7	3738-3741	and	abstract[234]|substance[236]	giv[234]|new[236]	_	_
27-8	3742-3752	tryptophan	abstract[234]|substance[236]|substance	giv[234]|new[236]|giv	coref	30-18
27-9	3753-3756	are	_	_	_	_
27-10	3757-3765	achieved	_	_	_	_
27-11	3766-3772	within	_	_	_	_
27-12	3773-3775	an	time[238]	new[238]	_	_
27-13	3776-3780	hour	time[238]	new[238]	_	_
27-14	3781-3783	of	time[238]	new[238]	_	_
27-15	3784-3793	ingestion	time[238]|event	new[238]|giv	_	_
27-16	3794-3795	,	_	_	_	_
27-17	3796-3801	which	_	_	_	_
27-18	3802-3804	is	_	_	_	_
27-19	3805-3813	followed	_	_	_	_
27-20	3814-3816	by	_	_	_	_
27-21	3817-3822	rapid	abstract[240]	new[240]	_	_
27-22	3823-3832	decreases	abstract[240]	new[240]	_	_
27-23	3833-3835	as	_	_	_	_
27-24	3836-3839	the	substance[242]	giv[242]	coref	28-17[246_242]
27-25	3840-3845	amino	object|substance[242]	giv|giv[242]	_	_
27-26	3846-3851	acids	substance[242]	giv[242]	_	_
27-27	3852-3855	are	_	_	_	_
27-28	3856-3867	metabolized	_	_	_	_
27-29	3868-3869	.	_	_	_	_

#Text=Glycine metabolizes various end-products , namely glutathione , nucleic acid bases , heme , creatine and bile acids .
28-1	3870-3877	Glycine	substance	giv	coref	29-12
28-2	3878-3889	metabolizes	_	_	_	_
28-3	3890-3897	various	substance[244]	new[244]	appos	28-6[245_244]
28-4	3898-3910	end-products	substance[244]	new[244]	_	_
28-5	3911-3912	,	_	_	_	_
28-6	3913-3919	namely	substance[245]	giv[245]	coref	29-27[0_245]
28-7	3920-3931	glutathione	substance[245]	giv[245]	_	_
28-8	3932-3933	,	substance[245]	giv[245]	_	_
28-9	3934-3941	nucleic	substance[245]	giv[245]	_	_
28-10	3942-3946	acid	substance[245]	giv[245]	_	_
28-11	3947-3952	bases	substance[245]	giv[245]	_	_
28-12	3953-3954	,	substance[245]	giv[245]	_	_
28-13	3955-3959	heme	substance[245]	giv[245]	_	_
28-14	3960-3961	,	substance[245]	giv[245]	_	_
28-15	3962-3970	creatine	substance[245]	giv[245]	_	_
28-16	3971-3974	and	_	_	_	_
28-17	3975-3979	bile	substance[246]	giv[246]	_	_
28-18	3980-3985	acids	substance[246]	giv[246]	_	_
28-19	3986-3987	.	_	_	_	_

#Text=The increases in urinary creatinine excretion and creatinine clearance following the glycine challenge suggest that glycine might be partially absorbed back and metabolized to creatinine through creatine .
29-1	3988-3991	The	event[247]	new[247]	coref	31-4[270_247]
29-2	3992-4001	increases	event[247]	new[247]	_	_
29-3	4002-4004	in	event[247]	new[247]	_	_
29-4	4005-4012	urinary	event[247]|person|abstract[250]|abstract[251]	new[247]|giv|giv[250]|giv[251]	coref|coref	31-12|31-12[276_250]
29-5	4013-4023	creatinine	event[247]|substance|abstract[250]|abstract[251]	new[247]|new|giv[250]|giv[251]	coref	29-8
29-6	4024-4033	excretion	event[247]|abstract[250]|abstract[251]	new[247]|giv[250]|giv[251]	_	_
29-7	4034-4037	and	event[247]|abstract[251]	new[247]|giv[251]	_	_
29-8	4038-4048	creatinine	event[247]|abstract[251]|substance|abstract[253]	new[247]|giv[251]|giv|giv[253]	coref	29-25[257_0]
29-9	4049-4058	clearance	event[247]|abstract[251]|abstract[253]	new[247]|giv[251]|giv[253]	_	_
29-10	4059-4068	following	_	_	_	_
29-11	4069-4072	the	event[255]	new[255]	_	_
29-12	4073-4080	glycine	substance|event[255]	giv|new[255]	coref	29-16
29-13	4081-4090	challenge	event[255]	new[255]	_	_
29-14	4091-4098	suggest	_	_	_	_
29-15	4099-4103	that	_	_	_	_
29-16	4104-4111	glycine	substance	giv	coref	30-16
29-17	4112-4117	might	_	_	_	_
29-18	4118-4120	be	_	_	_	_
29-19	4121-4130	partially	_	_	_	_
29-20	4131-4139	absorbed	_	_	_	_
29-21	4140-4144	back	_	_	_	_
29-22	4145-4148	and	_	_	_	_
29-23	4149-4160	metabolized	_	_	_	_
29-24	4161-4163	to	_	_	_	_
29-25	4164-4174	creatinine	substance[257]	giv[257]	coref	30-29[268_257]
29-26	4175-4182	through	substance[257]	giv[257]	_	_
29-27	4183-4191	creatine	substance[257]|substance	giv[257]|giv	_	_
29-28	4192-4193	.	_	_	_	_

#Text=Conversely , these urinary parameters did not change in response to the simultaneous supplementation with glycine and tryptophan , suggesting the suppression of the conversion of glycine to creatinine by tryptophan .
30-1	4194-4204	Conversely	_	_	_	_
30-2	4205-4206	,	_	_	_	_
30-3	4207-4212	these	abstract[259]	new[259]	_	_
30-4	4213-4220	urinary	abstract[259]	new[259]	_	_
30-5	4221-4231	parameters	abstract[259]	new[259]	_	_
30-6	4232-4235	did	_	_	_	_
30-7	4236-4239	not	_	_	_	_
30-8	4240-4246	change	_	_	_	_
30-9	4247-4249	in	_	_	_	_
30-10	4250-4258	response	abstract[260]	new[260]	coref	31-19[0_260]
30-11	4259-4261	to	abstract[260]	new[260]	_	_
30-12	4262-4265	the	abstract[260]|abstract[261]	new[260]|giv[261]	coref	31-21[278_261]
30-13	4266-4278	simultaneous	abstract[260]|abstract[261]	new[260]|giv[261]	_	_
30-14	4279-4294	supplementation	abstract[260]|abstract[261]	new[260]|giv[261]	_	_
30-15	4295-4299	with	abstract[260]|abstract[261]	new[260]|giv[261]	_	_
30-16	4300-4307	glycine	abstract[260]|abstract[261]|substance|substance[263]	new[260]|giv[261]|giv|giv[263]	coref|coref	30-27|14-7[0_263]
30-17	4308-4311	and	abstract[260]|abstract[261]|substance[263]	new[260]|giv[261]|giv[263]	_	_
30-18	4312-4322	tryptophan	abstract[260]|abstract[261]|substance[263]|substance	new[260]|giv[261]|giv[263]|giv	coref	30-31
30-19	4323-4324	,	_	_	_	_
30-20	4325-4335	suggesting	_	_	_	_
30-21	4336-4339	the	event[265]	new[265]	_	_
30-22	4340-4351	suppression	event[265]	new[265]	_	_
30-23	4352-4354	of	event[265]	new[265]	_	_
30-24	4355-4358	the	event[265]|event[266]	new[265]|new[266]	_	_
30-25	4359-4369	conversion	event[265]|event[266]	new[265]|new[266]	_	_
30-26	4370-4372	of	event[265]|event[266]	new[265]|new[266]	_	_
30-27	4373-4380	glycine	event[265]|event[266]|substance	new[265]|new[266]|giv	coref	31-13
30-28	4381-4383	to	event[265]|event[266]	new[265]|new[266]	_	_
30-29	4384-4394	creatinine	event[265]|event[266]|substance[268]	new[265]|new[266]|giv[268]	_	_
30-30	4395-4397	by	event[265]|event[266]|substance[268]	new[265]|new[266]|giv[268]	_	_
30-31	4398-4408	tryptophan	event[265]|event[266]|substance[268]|substance	new[265]|new[266]|giv[268]|giv	coref	31-25[281_0]
30-32	4409-4410	.	_	_	_	_

#Text=In fact , the increases in the serum glycine/creatinine ratio and urinary glycine excretion were more pronounced in response to supplementation with glycine and tryptophan than with glycine alone .
31-1	4411-4413	In	_	_	_	_
31-2	4414-4418	fact	_	_	_	_
31-3	4419-4420	,	_	_	_	_
31-4	4421-4424	the	event[270]	giv[270]	_	_
31-5	4425-4434	increases	event[270]	giv[270]	_	_
31-6	4435-4437	in	event[270]	giv[270]	_	_
31-7	4438-4441	the	event[270]|quantity[273]	giv[270]|new[273]	_	_
31-8	4442-4447	serum	event[270]|substance|quantity[273]	giv[270]|giv|new[273]	coref	34-19
31-9	4448-4466	glycine/creatinine	event[270]|substance|quantity[273]	giv[270]|new|new[273]	_	_
31-10	4467-4472	ratio	event[270]|quantity[273]	giv[270]|new[273]	_	_
31-11	4473-4476	and	event[270]	giv[270]	_	_
31-12	4477-4484	urinary	event[270]|person|abstract[276]	giv[270]|giv|giv[276]	coref	32-20[291_276]
31-13	4485-4492	glycine	event[270]|substance|abstract[276]	giv[270]|giv|giv[276]	coref	31-23
31-14	4493-4502	excretion	event[270]|abstract[276]	giv[270]|giv[276]	_	_
31-15	4503-4507	were	_	_	_	_
31-16	4508-4512	more	_	_	_	_
31-17	4513-4523	pronounced	_	_	_	_
31-18	4524-4526	in	_	_	_	_
31-19	4527-4535	response	abstract	giv	coref	35-23[323_0]
31-20	4536-4538	to	_	_	_	_
31-21	4539-4554	supplementation	abstract[278]	giv[278]	coref	35-27[327_278]
31-22	4555-4559	with	abstract[278]	giv[278]	_	_
31-23	4560-4567	glycine	abstract[278]|substance|substance[280]	giv[278]|giv|giv[280]	coref|coref	31-28[282_0]|35-25[325_0]
31-24	4568-4571	and	abstract[278]|substance[280]	giv[278]|giv[280]	_	_
31-25	4572-4582	tryptophan	abstract[278]|substance[280]|substance[281]	giv[278]|giv[280]|giv[281]	coref	32-13[0_281]
31-26	4583-4587	than	abstract[278]|substance[280]|substance[281]	giv[278]|giv[280]|giv[281]	_	_
31-27	4588-4592	with	abstract[278]|substance[280]|substance[281]	giv[278]|giv[280]|giv[281]	_	_
31-28	4593-4600	glycine	abstract[278]|substance[280]|substance[281]|substance[282]	giv[278]|giv[280]|giv[281]|giv[282]	coref	32-18[288_282]
31-29	4601-4606	alone	abstract[278]|substance[280]|substance[281]|substance[282]	giv[278]|giv[280]|giv[281]|giv[282]	_	_
31-30	4607-4608	.	_	_	_	_

#Text=Further studies are required to clarify the mechanism underlying the contribution of tryptophan to the effects of glycine on uric acid excretion .
32-1	4609-4616	Further	abstract[283]	giv[283]	coref	35-1[317_283]
32-2	4617-4624	studies	abstract[283]	giv[283]	_	_
32-3	4625-4628	are	_	_	_	_
32-4	4629-4637	required	_	_	_	_
32-5	4638-4640	to	_	_	_	_
32-6	4641-4648	clarify	_	_	_	_
32-7	4649-4652	the	abstract[284]	new[284]	_	_
32-8	4653-4662	mechanism	abstract[284]	new[284]	_	_
32-9	4663-4673	underlying	_	_	_	_
32-10	4674-4677	the	abstract[285]	new[285]	_	_
32-11	4678-4690	contribution	abstract[285]	new[285]	_	_
32-12	4691-4693	of	abstract[285]	new[285]	_	_
32-13	4694-4704	tryptophan	abstract[285]|substance	new[285]|giv	coref	33-48
32-14	4705-4707	to	_	_	_	_
32-15	4708-4711	the	abstract[287]	new[287]	_	_
32-16	4712-4719	effects	abstract[287]	new[287]	_	_
32-17	4720-4722	of	abstract[287]	new[287]	_	_
32-18	4723-4730	glycine	abstract[287]|substance[288]	new[287]|giv[288]	coref	33-43[304_288]
32-19	4731-4733	on	abstract[287]|substance[288]	new[287]|giv[288]	_	_
32-20	4734-4738	uric	abstract[287]|substance[288]|abstract|abstract[291]	new[287]|giv[288]|giv|giv[291]	coref	34-20
32-21	4739-4743	acid	abstract[287]|substance[288]|substance|abstract[291]	new[287]|giv[288]|giv|giv[291]	coref	34-21
32-22	4744-4753	excretion	abstract[287]|substance[288]|abstract[291]	new[287]|giv[288]|giv[291]	_	_
32-23	4754-4755	.	_	_	_	_

#Text=Among the limitations in the current clinical study , the modest sample size ( n = 16 ) might have reduced the statistical power and increased the risk of type II error , particularly regarding the statistical differences in multiple comparisons between the glycine and glycine + tryptophan groups .
33-1	4756-4761	Among	_	_	_	_
33-2	4762-4765	the	abstract[292]	new[292]	_	_
33-3	4766-4777	limitations	abstract[292]	new[292]	_	_
33-4	4778-4780	in	abstract[292]	new[292]	_	_
33-5	4781-4784	the	abstract[292]|event[293]	new[292]|giv[293]	coref	34-3[308_293]
33-6	4785-4792	current	abstract[292]|event[293]	new[292]|giv[293]	_	_
33-7	4793-4801	clinical	abstract[292]|event[293]	new[292]|giv[293]	_	_
33-8	4802-4807	study	abstract[292]|event[293]	new[292]|giv[293]	_	_
33-9	4808-4809	,	_	_	_	_
33-10	4810-4813	the	quantity[295]	new[295]	_	_
33-11	4814-4820	modest	quantity[295]	new[295]	_	_
33-12	4821-4827	sample	object|quantity[295]	new|new[295]	_	_
33-13	4828-4832	size	quantity[295]	new[295]	_	_
33-14	4833-4834	(	_	_	_	_
33-15	4835-4836	n	quantity	new	_	_
33-16	4837-4838	=	_	_	_	_
33-17	4839-4841	16	quantity	new	_	_
33-18	4842-4843	)	_	_	_	_
33-19	4844-4849	might	_	_	_	_
33-20	4850-4854	have	_	_	_	_
33-21	4855-4862	reduced	_	_	_	_
33-22	4863-4866	the	abstract[298]	new[298]	_	_
33-23	4867-4878	statistical	abstract[298]	new[298]	_	_
33-24	4879-4884	power	abstract[298]	new[298]	_	_
33-25	4885-4888	and	_	_	_	_
33-26	4889-4898	increased	_	_	_	_
33-27	4899-4902	the	abstract[299]	new[299]	_	_
33-28	4903-4907	risk	abstract[299]	new[299]	_	_
33-29	4908-4910	of	abstract[299]	new[299]	_	_
33-30	4911-4915	type	abstract[299]|abstract	new[299]|new	appos	33-31[301_0]
33-31	4916-4918	II	abstract[301]	giv[301]	_	_
33-32	4919-4924	error	abstract[301]	giv[301]	_	_
33-33	4925-4926	,	_	_	_	_
33-34	4927-4939	particularly	_	_	_	_
33-35	4940-4949	regarding	_	_	_	_
33-36	4950-4953	the	abstract[302]	new[302]	coref	34-16[312_302]
33-37	4954-4965	statistical	abstract[302]	new[302]	_	_
33-38	4966-4977	differences	abstract[302]	new[302]	_	_
33-39	4978-4980	in	abstract[302]	new[302]	_	_
33-40	4981-4989	multiple	abstract[302]|abstract[303]	new[302]|new[303]	_	_
33-41	4990-5001	comparisons	abstract[302]|abstract[303]	new[302]|new[303]	_	_
33-42	5002-5009	between	abstract[302]|abstract[303]	new[302]|new[303]	_	_
33-43	5010-5013	the	abstract[302]|abstract[303]|substance[304]	new[302]|new[303]|giv[304]	coref	33-46[0_304]
33-44	5014-5021	glycine	abstract[302]|abstract[303]|substance[304]	new[302]|new[303]|giv[304]	_	_
33-45	5022-5025	and	abstract[302]|abstract[303]	new[302]|new[303]	_	_
33-46	5026-5033	glycine	abstract[302]|abstract[303]|substance	new[302]|new[303]|giv	coref	35-25
33-47	5034-5035	+	abstract[302]|abstract[303]	new[302]|new[303]	_	_
33-48	5036-5046	tryptophan	abstract[302]|abstract[303]|substance|person[307]	new[302]|new[303]|giv|new[307]	coref	35-27
33-49	5047-5053	groups	abstract[302]|abstract[303]|person[307]	new[302]|new[303]|new[307]	_	_
33-50	5054-5055	.	_	_	_	_

#Text=Furthermore , the current study included only male subjects because of the known effects of sex differences on serum uric acid levels .
34-1	5056-5067	Furthermore	_	_	_	_
34-2	5068-5069	,	_	_	_	_
34-3	5070-5073	the	event[308]	giv[308]	_	_
34-4	5074-5081	current	event[308]	giv[308]	_	_
34-5	5082-5087	study	event[308]	giv[308]	_	_
34-6	5088-5096	included	_	_	_	_
34-7	5097-5101	only	abstract[309]	new[309]	_	_
34-8	5102-5106	male	abstract[309]	new[309]	_	_
34-9	5107-5115	subjects	abstract[309]	new[309]	_	_
34-10	5116-5123	because	abstract[309]	new[309]	_	_
34-11	5124-5126	of	abstract[309]	new[309]	_	_
34-12	5127-5130	the	abstract[309]|abstract[310]	new[309]|new[310]	_	_
34-13	5131-5136	known	abstract[309]|abstract[310]	new[309]|new[310]	_	_
34-14	5137-5144	effects	abstract[309]|abstract[310]	new[309]|new[310]	_	_
34-15	5145-5147	of	abstract[309]|abstract[310]	new[309]|new[310]	_	_
34-16	5148-5151	sex	abstract[309]|abstract[310]|event|abstract[312]	new[309]|new[310]|new|giv[312]	coref	35-15[320_312]
34-17	5152-5163	differences	abstract[309]|abstract[310]|abstract[312]	new[309]|new[310]|giv[312]	_	_
34-18	5164-5166	on	abstract[309]|abstract[310]|abstract[312]	new[309]|new[310]|giv[312]	_	_
34-19	5167-5172	serum	abstract[309]|abstract[310]|abstract[312]|abstract|abstract[316]	new[309]|new[310]|giv[312]|giv|giv[316]	_	_
34-20	5173-5177	uric	abstract[309]|abstract[310]|abstract[312]|abstract|abstract[316]	new[309]|new[310]|giv[312]|giv|giv[316]	_	_
34-21	5178-5182	acid	abstract[309]|abstract[310]|abstract[312]|substance|abstract[316]	new[309]|new[310]|giv[312]|giv|giv[316]	_	_
34-22	5183-5189	levels	abstract[309]|abstract[310]|abstract[312]|abstract[316]	new[309]|new[310]|giv[312]|giv[316]	_	_
34-23	5190-5191	.	_	_	_	_

#Text=Further studies are therefore needed , although our preliminary findings suggested that there were no effective differences between males and females in response to glycine and tryptophan supplementation ( data not shown ) .
35-1	5192-5199	Further	abstract[317]	giv[317]	_	_
35-2	5200-5207	studies	abstract[317]	giv[317]	_	_
35-3	5208-5211	are	_	_	_	_
35-4	5212-5221	therefore	_	_	_	_
35-5	5222-5228	needed	_	_	_	_
35-6	5229-5230	,	_	_	_	_
35-7	5231-5239	although	_	_	_	_
35-8	5240-5243	our	person|abstract[319]	acc|new[319]	_	_
35-9	5244-5255	preliminary	abstract[319]	new[319]	_	_
35-10	5256-5264	findings	abstract[319]	new[319]	_	_
35-11	5265-5274	suggested	_	_	_	_
35-12	5275-5279	that	_	_	_	_
35-13	5280-5285	there	_	_	_	_
35-14	5286-5290	were	_	_	_	_
35-15	5291-5293	no	abstract[320]	giv[320]	_	_
35-16	5294-5303	effective	abstract[320]	giv[320]	_	_
35-17	5304-5315	differences	abstract[320]	giv[320]	_	_
35-18	5316-5323	between	abstract[320]	giv[320]	_	_
35-19	5324-5329	males	abstract[320]|person	giv[320]|new	_	_
35-20	5330-5333	and	abstract[320]	giv[320]	_	_
35-21	5334-5341	females	abstract[320]|person[322]	giv[320]|new[322]	_	_
35-22	5342-5344	in	abstract[320]|person[322]	giv[320]|new[322]	_	_
35-23	5345-5353	response	abstract[320]|person[322]|abstract[323]	giv[320]|new[322]|giv[323]	_	_
35-24	5354-5356	to	abstract[320]|person[322]|abstract[323]	giv[320]|new[322]|giv[323]	_	_
35-25	5357-5364	glycine	abstract[320]|person[322]|abstract[323]|substance|substance[325]	giv[320]|new[322]|giv[323]|giv|giv[325]	_	_
35-26	5365-5368	and	abstract[320]|person[322]|abstract[323]|substance[325]	giv[320]|new[322]|giv[323]|giv[325]	_	_
35-27	5369-5379	tryptophan	abstract[320]|person[322]|abstract[323]|substance[325]|substance|abstract[327]	giv[320]|new[322]|giv[323]|giv[325]|giv|giv[327]	_	_
35-28	5380-5395	supplementation	abstract[320]|person[322]|abstract[323]|substance[325]|abstract[327]	giv[320]|new[322]|giv[323]|giv[325]|giv[327]	_	_
35-29	5396-5397	(	_	_	_	_
35-30	5398-5402	data	abstract	new	_	_
35-31	5403-5406	not	_	_	_	_
35-32	5407-5412	shown	_	_	_	_
35-33	5413-5414	)	_	_	_	_
35-34	5415-5416	.	_	_	_	_
